Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co-Promote Antibodies for Treatment of Parkinson's Disease
11 déc. 2013 16h05 HE
|
Prothena Corporation plc
Prothena to receive up to $600 million, inclusive of upfront payment and near-term clinical milestone totaling $45 million, as well as 30 percent of U.S. profits, and up to double-digit royalties...
Prothena Reports Third Quarter 2013 Financial Results
12 nov. 2013 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Research and Development Day and Webcast
28 oct. 2013 09h01 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Pricing of Public Offering of 5,910,000 Ordinary Shares
03 oct. 2013 06h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena Reports Second Quarter 2013 Financial Results
12 août 2013 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena to Present at the Wedbush Securities Life Sciences Management Access Conference in New York
07 août 2013 16h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena Welcomes New Director to Its Board
22 juil. 2013 16h30 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 22, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena to Present at the Eighth Annual JMP Securities Healthcare Conference in New York
01 juil. 2013 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, July 1, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena Shares to Be Added to Russell Global Index
17 juin 2013 17h00 HE
|
Prothena Corporation plc
DUBLIN, Ireland, June 17, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena to Present at the Jefferies 2013 Global Healthcare Conference in New York
29 mai 2013 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, May 29, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...